First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations

AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The ...

Related Keywords

Japan ,Germany ,United States ,United Kingdom ,Italy ,Cambridge ,Cambridgeshire ,France ,Spain ,America ,Lymphopoietin Isoforms ,Astrazeneca Tezspire ,Pneumologie Mainz ,Thoraxklinik Heidelberg ,Stephanie Korn ,Amgen ,Company On Twitter ,Tezspire Summary Of Committee ,Nasdaq ,World Allergy Organization ,Astrazeneca ,Investor Relations Team ,European Union ,European Medicines Agency ,Global Asthma Network ,Committee For Medicinal Products Human Use ,Airways Of Human Asthmatics In Vivo ,Medicinal Products ,Human Use ,Senior Physician ,Respiratory Medicine ,Executive Vice President ,New England Journal ,Therapy Designation ,Priority Review ,Orphan Drug Designation ,Rare Diseases ,Stromal Lymphopoietin Isoforms ,Inflammatory Disorders ,Human Asthmatics In Vivo ,Potential Biomarker ,Severe Refractory ,Tezspire Summary ,Human Use Opinion Available ,Eur Respir ,Global Asthma ,Global Asthma Report ,Possible Explanation ,Explor Res Hypothesis ,Ann Allergy Asthma ,Illness Among Patients ,Severe Asthma ,Managed Care ,Care Respir ,Allergy Organization ,Lancet Respir ,Adolescents With Severe ,Uncontrolled Asthma ,